Table 3.
Outcomes.
| Success group |
Rebound group |
Refractory group |
|
|---|---|---|---|
| (n = 83, 73.5%) | (n = 9, 8.0%) | (n = 21, 18.6%) | |
| Time from onset to rebound, days | 12 (11–13)a | ||
| Time from the start of steroids to 2-steps improvement of the clinical status on a 7-point ordinal scale, days | |||
| 7 (6–9) | 14 (10–17) | 15 (13–19)b | |
| Treatment and outcome after rebound or refractory, n | |||
| Improvement without resuming steroids | 4 (44.4) | 9 (42.9) | |
| Improvement after resuming steroids | 5 (55.6) | 0 (0) | |
| Improvement after methylprednisolone pulse | 0 (0) | 3 (14.3) | |
| Improvement after increasing steroids | 0 (0) | 1 (4.8) | |
| Death after methylprednisolone pulse | 0 (0) | 6 (28.6) | |
| Death after increasing steroids | 0 (0) | 1 (4.8) | |
| Death without steroid modification | 0 (0) | 1 (4.8) | |
| Death, n | 0 (0) | 0 (0) | 8 (38.1) |
a
n (%) or median (interquartile range).
b
Eight patients who died without any improvement in clinical status on a 7-point ordinal scale were not included.